NASDAQ:BCLI

Brainstorm Cell Therapeutics Earnings Date, Estimates & History

$3.90
+0.14 (+3.72 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.78
$3.92
50-Day Range
$3.01
$3.97
52-Week Range
$2.92
$17.95
Volume305,835 shs
Average Volume826,160 shs
Market Capitalization$141.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.02

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earnings Information

Brainstorm Cell Therapeutics last posted its earnings results on April 25th, 2021. The biotechnology company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. Brainstorm Cell Therapeutics has generated ($1.07) earnings per share over the last year. Brainstorm Cell Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 4th, 2021 based off prior year's report dates.

Brainstorm Cell Therapeutics Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20211($0.24)($0.24)($0.24)

Brainstorm Cell Therapeutics (NASDAQ BCLI) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
8/4/2021
(Estimated)
       
4/25/20213/31/2021($0.26)($0.19)($0.19)Transcript
2/3/202112/31/2020($0.48)($0.37)($0.37)Transcript
10/15/20209/30/2020($0.26)($0.14)($0.14)Transcript
8/5/20206/30/2020($0.26)($0.25)($0.25)Transcript
5/7/20203/31/2020($0.23)($0.32)($0.32)Listen
2/18/2020Q4 2019($0.21)($0.3381)($0.34)Transcript
11/14/2019Q3($0.22)($0.25)($0.25)$1.50 millionTranscript
8/13/20196/30/2019($0.11)($0.23)($0.23)$1.50 millionN/A
5/10/2019Q1 2019($0.06)($0.24)($0.24)N/A
3/29/2019Q4 2018($0.26)($0.26)N/A
10/29/20189/30/2018($0.10)($0.15)($0.15)$1.50 millionN/A
7/23/2018Q2 2018($0.14)($0.16)($0.16)$1.50 millionN/A
5/14/2018Q1 2018($0.14)($0.12)($0.12)N/A
3/8/2018Q4 2017($0.09)$0.02$0.02Transcript
10/17/2017Q3 2017($0.16)($0.13)($0.13)N/A
8/14/2017Q2 2017($0.10)($0.06)($0.06)N/A
5/15/2017Q1 2017($0.30)($0.10)($0.10)N/A
3/30/2017Q4 2016($0.07)($0.0330)($0.03)N/A
11/14/2016Q3 2016($0.11)($0.09)($0.09)N/A
8/11/2016Q2($0.18)($0.05)($0.05)N/A
5/10/2016Q116($0.25)($0.10)($0.10)N/A
3/10/2016Q415($0.15)($0.07)($0.07)N/A
11/17/2015Q3($0.14)($0.14)($0.14)N/A
8/13/2015Q215($0.13)($0.12)($0.12)Listen
5/14/2015Q115($0.14)($0.12)($0.12)Listen
3/26/2015Q414($0.18)($0.18)($0.18)N/A
11/13/2014($0.12)($0.16)N/A
11/13/2014Q3 14($0.12)($0.16)($0.16)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.